Renovis, Inc announced last week that it intends to file a proposed underwritten public offering of common stock amounting to 4,000,000 primary shares. Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The most advanced product candidate, Cerovive, is exclusively licensed to AstraZeneca AB and is in Phase III clinical trials for acute ischemic stroke. Corporate profile which may be of interest to investors may be found here.

GTx, Inc. announced last week that it is offering to sell 5,000,000 shares of newly issued common stock. GTx is a biopharmaceutical company developing therapeutics for cancer and serious conditions related to men's health, focusing on small molecules that selectively modulate the effects of estrogens and androgens. Click here for more stock and investment information.

Myogen, Inc. announced last week the pricing of an underwritten public offering of 4,675,082 shares of newly issued common stock at $23.25 per share. Myogen has two product candidates in late-stage clinical development: ambrisentan for the treatment of pulmonary arterial hypertension and darusentan for the treatment of resistant systolic hypertension. In collaboration with Novartis, Myogen also conducts a target and drug discovery research program for the treatment of chronic heart failure and related cardiovascular disorders. More information for investors here.